- call +1-201-465-4211
- email sales@mrinsights.biz
Publish Date: Jan, 2019|Report ID: 141130|Price: $3480
African horse sickness (AHS) is a serious arthropod borne viral di ease ofequids, with a mortality rate that can reach 95% in some species, such as horses. Scope of the Report:This report focuses on the African Horse Sic...
Know MorePublish Date: Jan, 2019|Report ID: 141129|Price: $4880
Aflatoxicosis is the most prevalent, highly toxic, carcinogenic and economically significant mycotoxins consumed by poultry.Scope of the Report:This report focuses on the Aflatoxicosis Treatment in global market, especia...
Know MorePublish Date: Jan, 2019|Report ID: 141128|Price: $3480
Aflatoxicosis is the most prevalent, highly toxic, carcinogenic and economically significant mycotoxins consumed by poultry.Scope of the Report:This report focuses on the Aflatoxicosis Treatment in global market, especia...
Know MorePublish Date: Jan, 2019|Report ID: 141117|Price: $4880
Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be u...
Know MorePublish Date: Jan, 2019|Report ID: 141116|Price: $3480
Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be u...
Know MorePublish Date: Jan, 2019|Report ID: 141115|Price: $4880
Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be u...
Know MorePublish Date: Jan, 2019|Report ID: 141114|Price: $3480
Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be u...
Know MorePublish Date: Jan, 2019|Report ID: 141113|Price: $4880
Nilotinib in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.Scope of the Report:This rep...
Know MorePublish Date: Jan, 2019|Report ID: 141112|Price: $3480
Nilotinib in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.Scope of the Report:This rep...
Know MorePublish Date: Jan, 2019|Report ID: 141111|Price: $4880
Nilotinib in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.Scope of the Report:This rep...
Know More